Investment Thesis
Sutro Biopharma exhibits critical financial distress with negative stockholders' equity of -$132.5M and annual operating cash burn of -$177.2M against only $58.1M in cash reserves, providing less than 4 months of runway. While revenue growth of 65.2% YoY demonstrates commercial traction, the company's massive operating losses (-$158.4M), negative net margin (-186.5%), and technically insolvent balance sheet indicate the business model is not yet viable and imminent capital restructuring is highly likely.
Strengths
- Strong revenue growth momentum at 65.2% YoY suggests market adoption of products
- Current ratio of 2.01x indicates adequate short-term liquidity position
- Insider activity with 6 Form 4 filings in 90 days shows continued stakeholder engagement
Risks
- Negative stockholders' equity of -$132.5M indicates technical insolvency with liabilities exceeding assets
- Severe operating cash burn of -$177.2M annually with only $58.1M cash provides critical runway of ~4 months
- Operating margin of -154.5% and net margin of -186.5% with no visible path to profitability
- Likely imminent capital raise will be highly dilutive to existing shareholders
- Unsustainable cash burn rate will force restructuring or bankruptcy if revenue does not dramatically accelerate profitability
Key Metrics to Watch
- Cash runway and monthly burn rate trends
- Revenue growth sustainability and gross margin expansion potential
- Operating expense reduction progress and path to operating breakeven
- Debt refinancing capability and equity raise completion status
Financial Metrics
Revenue
102.5M
Net Income
-191.1M
EPS (Diluted)
$-22.49
Free Cash Flow
-178.0M
Total Assets
173.8M
Cash
58.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-154.5%
Net Margin
-186.5%
ROE
N/A
ROA
-109.9%
FCF Margin
-173.7%
Balance Sheet & Liquidity
Current Ratio
2.01x
Quick Ratio
2.01x
Debt/Equity
N/A
Debt/Assets
176.2%
Interest Coverage
-121.82x
Long-term Debt
4.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T19:12:20.940250 |
Data as of: 2025-12-31 |
Powered by Claude AI